Dermira launching Qbrexza for primary axillary hyperhidrosis

Dermira Inc. (NASDAQ:DERM) will launch Qbrexza glycopyrronium tosylate to treat primary axillary hyperhidrosis in patients ages nine and older on Oct. 1. The topical anticholinergic agent, which FDA approved in June, will be priced at $550 for a 30-day supply. Dermira vowed to not increase Qbrexza’s list price in 2019.

Qbrexza is the first topical treatment for excessive underarm sweat, according to Dermira...